Drug Profile

ENOB DC 12 XX

Alternative Names: ENOB-DC-12-XX; RENB DC 12 XX

Latest Information Update: 21 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Enochian BioSciences
Developer Renovaro Biosciences
Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Gene therapies; Immunotherapies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

09 Aug 2023 Enochian BioSciences is now called Renovaro Biosciences
28 Feb 2023 Preclinical trials in Solid tumours in USA (Parenteral) (Enochian BioSciences pipeline, February 2023)
16 Aug 2022 Enochian BioSciences has patent protection for ENOB DC 12 XX in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com